Pier­is AG

Pier­is is devel­op­ing a new gen­er­a­tion of pro­tein thera­peut­ics with its pro­pri­et­ary Antic­al­in tech­no­logy, which will sig­ni­fic­antly con­trib­ute to patient com­fort due to high­er effi­ciency and safety.

Based on Pier­is’ expert­ise in drug research and devel­op­ment, the cur­rent pipeline con­sists of intern­al devel­op­ment pro­jects in onco­logy, immun­o­logy and anemia, as well as col­lab­or­a­tion pro­jects with phar­ma­ceut­ic­al com­pan­ies such as San­ofi and Daii­chi Sankyo. The com­pany has a broad pat­ent port­fo­lio and is fun­ded by investors such as OrbiMed Advisors, For­bion, Glob­al Life Sci­ence Ven­tures and oth­er ven­ture cap­it­al firms.